A Breakthrough in Cancer Treatment: CAR-NKT Immunotherapy Targets Triple-Negative Breast Cancer
Scientists at UCLA have developed a groundbreaking cell-based immunotherapy that could revolutionize the treatment of triple-negative breast cancer (TNBC), a highly aggressive form of cancer with limited treatment options. The innovative therapy, known as CAR-NKT cell therapy, combines the power of invariant natural killer T cells (NKT cells) with a chimeric antigen receptor (CAR) to target the protein mesothelin, which is present on TNBC cells. This approach harnesses multiple immune mechanisms to effectively combat tumors.
In a recent study published in the Journal of Hematology & Oncology, the researchers described the development of CAR-NKT cells, which have shown remarkable cancer-fighting capabilities. Lead researcher Yanruide (Charlie) Li, PhD, explains, "We're not just targeting one molecular marker on cancer cells; we're identifying dozens of them simultaneously. It's like attacking a fortress from every direction at once. The cancer simply can’t adapt fast enough to escape."
The CAR-NKT therapy employs three distinct mechanisms to recognize and destroy solid tumors. Firstly, the engineered CAR targets mesothelin, a protein associated with aggressive and metastatic TNBC. Secondly, NKT cells' receptors recognize over 20 molecular markers, making it nearly impossible for tumors to evade their attack. Lastly, a unique T cell receptor reshapes the tumor microenvironment by eliminating immunosuppressive cells.
The therapy's effectiveness was demonstrated in late-stage metastatic TNBC tumor samples, where CAR-NKT cells successfully killed cancer cells and eliminated immunosuppressive cells that often shield tumors from treatment. This is a significant advancement, as current CAR T cell therapies, while effective against certain blood cancers, have struggled with solid tumors due to tumor heterogeneity, immune evasion, and the complexity of the solid tumor microenvironment.
One of the key advantages of CAR-NKT therapy is its potential accessibility and affordability. Unlike CAR T cell therapies, which are engineered from individual patient's immune cells and can cost over $100,000, CAR-NKT therapy can be mass-produced from donated blood cells. A single blood donation can yield thousands of treatments, reducing the cost to around $5,000 per dose. This makes it a more viable option for a broader range of patients.
The development of CAR-NKT therapy was informed by previous research identifying mesothelin as a CAR target and earlier UCLA studies showing that NKT cells could reshape tumor microenvironments. To enhance the therapy's persistence and reduce immune rejection, the team engineered a universal variant (U15MCAR-NKT) by deleting HLA-I and HLA-II molecules through CRISPR editing, ensuring resistance to host T cell-mediated allorejection while maintaining potent antitumor effects.
The versatility of CAR-NKT therapy extends beyond TNBC. Mesothelin is highly expressed in ovarian, pancreatic, and lung cancers, making it a potential target for these difficult-to-treat solid tumor types. The UCLA team is now preparing applications to the FDA to initiate clinical trials in both TNBC and ovarian cancer, marking a significant step forward in cancer treatment.
